Peptidomimetic Inhibitors for Treatment of Alzheimer's Disease
- Summary
- Researchers at Purdue University have developed a series of novel compounds for beta-secretase inhibition that offer improved pharmacological properties. Novel peptidomimetic scaffolds were utilized to replace conventional hydroxyethylamine isosteres and were shown to be good inhibitors of beta-secretase. This series of compounds shows increased potency, improved aqueous solubility, increased metabolic stability, and improved oral bioavailability over previously identified inhibitors or beta-secretase.
- Technology Benefits
- Improved pharmacological propertiesShown to be good inhibitors of beta-secretase
- Technology Application
- Medical/HealthPharmaceutical Industry
- Detailed Technology Description
- Arun GhoshGhosh GroupPurdue Chemistry
- Countries
- United States
- Application No.
- 8,859,590
- *Abstract
-
- *Background
- Alzheimer's disease is a progressive mental deterioration, resulting in loss of memory, confusion and disorientation, and other behavioral problems. Unfortunately, no definitive cure has been developed to treat this disease. Beta-secretase, an important enzyme in the development and onset of Alzheimer's disease, contributes to the formation of amyloid-beta peptides that aggregate in the brain of Alzheimer's patients. Blocking beta-secretase is a potential strategy for the treatment of Alzheimer's disease.
- *IP Issue Date
- Oct 14, 2014
- *IP Type
- Utility
- *Stage of Development
- Concept Developed
- *Web Links
- Purdue Office of Technology CommercializationPurdueInnovation and EntrepreneurshipArun GhoshGhosh GroupPurdue Chemistry
- Country/Region
- USA
For more information, please click Here
